Filing Details
- Accession Number:
- 0001569706-18-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-06 17:26:40
- Reporting Period:
- 2018-10-29
- Accepted Time:
- 2018-11-06 17:26:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1018735 | Nymox Pharmaceutical Corp | NYMX | In Vitro & In Vivo Diagnostic Substances (2835) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1569706 | Paul Averback | C/O Nymox Pharmaceutical Corporation 9900 Cavendish Blvd., Suite 306 St. Laurent A8 H4M 2V2 | Ceo | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Common | Disposition | 2018-10-29 | 1,687,600 | $2.50 | 21,643,948 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Billionaire Hedge Funds
